Perspectum Group, which provides a portfolio of medical imaging software, announced terms for its IPO on Monday.
The Oxfordshire, United Kingdom-based company plans to raise $75 million by offering 4.7 million ADSs at a price range of $15 to $17. At the midpoint of the proposed range, Perspectum Group would command a fully diluted market value of $637 million.
Perspectum's software products combine image formation, magnetic resonance (MR) image analysis, and artificial intelligence (AI) to support healthcare provider diagnosis, treatment decision-making, and monitoring of the progression of chronic metabolic diseases, multi-organ pathologies, and cancer, and determine whether the patient is responding to therapy. Its product portfolio comprises cloud-based AI-driven software that utilizes medical images. Its flagship AI-driven product, LiverMultiScan, has been cleared by the FDA for non-invasive diagnosis and monitoring of liver disorders, which may include nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The company's SaaS platform products are currently enabled at approximately 350 locations worldwide.
Perspectum Group was founded in 2012 and booked $9 million in revenue for the 12 months ended March 31, 2021. It plans to list on the Nasdaq under the symbol SCAN. Citi, Barclays, Stifel, and Canaccord Genuity are the joint bookrunners on the deal. It is expected to price during the week of July 12, 2021.
